Business
Commercial launch of bowel cancer testing service
EDX Medical Group plc has commercially launched its BC95 bowel cancer testing service in the UK, which offers improved early detection with sensitivities exceeding 95% across all stages and includes an assessment of hereditary risk. This comprehensive service utilizes epigenetic biomarker testing, EarlyTect®-C, developed in partnership with Genomictree, alongside other methods like qFIT, to analyze biomarkers from faecal, blood, or saliva samples. The BC95 service aims to address the significant number of missed diagnoses in current screening methods, with the goal of improving patient outcomes and survival rates, which are closely linked to early diagnosis. Disclaimer*
About this update from Edx Medical Group Plc
[{"type":"text","content":"\n\nThis announcement contains inside information as stipulated under the UK version of the Market Abuse Regulation No 596/2014 which is part of English law by virtue of the European (Withdrawal) Act 2018, as amended. On publication of this announcement via a regulatory information service, this information is considered to be in the public domain.\n \n\n \n18 December 2025\nEDX Medical Group plc\nAQSE: EDX\n(\"EDX Medical\" or the \"Group\" or \"Company\")\n\n \nCOMMERCIAL LAUNCH OF COMPREHENSIVE BOWEL CANCER TESTING SERVICE (BC95)\n \n\nCAMBRIDGE, UK: EDX Medical Group plc, which develops innovative digital diagnostic products and services supporting personalised treatments for cancer, cardiovascular and infectious diseases, announces today the commercial launch in the UK of a new and comprehensive testing service that improves the early detection of bowel cancer.\n\n \nThe BC95 service, which will be available within the next few weeks, increases the accuracy of testing and includes an assessment of the patient's hereditary risk of bowel cancer. It is the most advanced and accurate testing solution to be offered in the UK with sensitivities in excess of 95% across stages 1 to 4 of bowel cancer. The EDX Medical BC95 bowel cancer service provides an analysis of a comprehensive panel of hereditary genetic risks, plus the most reliable early detection test and a reference test for faecal haemoglobin, enabling comparison to current NHS practice. \n\n \nBowel, or colorectal, cancer is the second most common cause of cancer-related deaths worldwide. In the UK alone, there are 44,000 new cases each year. Someone contracts bowel cancer every 10 minutes and every 30 minutes someone dies from the disease. 75% of all newly diagnosed cases are missed by current screening methods. \n \n\nThe BC95 service comprises a suite of diagnostic tests, that can be selected for individual patient needs. The testing service uses faecal and blood or saliva samples to examine a range of important biomarkers clinically validated for the detection of bowel cancer, pre-cancerous adenomas and an assessment of hereditary genetic risk. The results from the various tests are returned to the patient's designated healthcare provider or doctor for clinical follow-up.\n\n ...